Rapamycin (Sirolimus) Licensed by Pfizer

Catalog No.S1039

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

Price Stock Quantity  
USD 306 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Rapamycin (Sirolimus) Chemical Structure

Rapamycin (Sirolimus) Chemical Structure
Molecular Weight: 914.18

Validation & Quality Control

Cited by 59 publications:

12 customer reviews :

Quality Control & MSDS

Related Compound Libraries

mTOR Inhibitors with Unique Features

  • Pan mTOR inhibitor

    KU-0063794 mTORC1 and mTORC2, IC50=~10 nM.

  • FDA-approved mTOR Inhibitor

    Temsirolimus (CCI-779, NSC 683864) Approved by FDA for Renal Cell Carcinoma (RCC).

  • Newest mTOR Inhibitor

    XL388 Highly potent, selective, ATP-competitive inhibitor of mTOR with IC50 of 9.9 nM, 1000-fold selectivity over the closely related PI3K kinases.

  • Classic mTOR Inhibitor

    BEZ235 (NVP-BEZ235, Dactolisib) Dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM/5 nM/7 nM/75 nM/6 nM, respectively.

Product Information

  • Compare mTOR Inhibitors
    Compare mTOR Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Targets mTOR [1]
(HEK293 cells)
IC50 ~0.1 nM
In vitro Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
HT-29MXXDfZRwfG:6aXOgRZN{[Xl?NIC2R28yOCCwTR?=MXm3NkBpNFvJR4VFVVORM{Kz[nBwfGWwdHnheIV{KGOjbYD0c5Rp\WOrbj3pcoR2[2WmIHP5eI91d3irY3n0fS=>NV[wZ4l6OjR7MEC4O|M>
HT-29NFS2XnBEgXSxdH;4bYMhSXO|YYm=MWKxNEBvVQ>?MX:3NkBpNUDJTnFGTE2VTx?=M1fxR3BwfGWwdHnheIV{KGSrZ3n0c5hqdi2rbnT1Z4VlKGO7dH;0c5hq[2m2eR?=NXL4dmczOjR7MEC4O|M>
HT-29NVS3eWlqS3m2b4TvfIlkKEG|c3H5MlHpNVAhdk1?M13rdlczKGh?MkDzSG1UVw>?MkjIVI91\W62aXH0[ZMhPS2obIXvdo92emGlaXytbY5lfWOnZDDjfZRwfG:6aXPpeJk>MnLMNlQ6ODB6N{O=
PC3NEjQTm1McW6jc3WgRZN{[Xl?M1H1VVExOCCwTR?=NGTWU2QyKGh?NYPXc|V5TE2VTx?=M{LId3BwfGWwdHz5JIlvcGmkaYTzJI1VV1JvbXXkbYF1\WRiU{[gdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kA9OTBibl2uMlK0NlE6Pzh4OEO=
PC3NIXtNWtMcW6jc3WgRZN{[Xl?MVWxNFAhdk1?M2D3WlEhcA>?NHqzOJhFVVORNUL3NmtNTG:nczDuc5QhcW6qaXLpeEBuXE:ULX3l[IlifGWmIFHreEBxcG:|cHjvdplt[XSrb36=MkLuNlE6Pzh4OEO=
PC3M4nOS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2jqWFEvPSEQvF2=M1XQ[FEhcA>?Moe2SG1UVw>?M{T4Xmlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCSQ{OgZ4VtdHNid3n0bEBKSzVyIH;mJFwyOCCwTR?=NXjzTXRXOjF7N{i2PFM>
HEK293MWnGeY5kfGmxbjDBd5NigQ>?M3fk[|ExOCCwTR?=M3X4NVghcA>?M1nZWWROW09?NVXVWItnUW6qaXLpeJMhXFCDLXnu[JVk\WRiZHXndoFl[XSrb36gc4YhWGSlZESge4l1cCCHQ{WwJI9nKDVyIH7NMWSyNVU{QTNyMR?=
BT-20NXrPXYJLU2mwYYPlJGF{e2G7MkPENlAh|ryPMlK4SG1UVw>?M2T5d2Rw\XNibn;0JIlvcGmkaYSgcXRQWkN{IHTldIVv\GWwdDDwRYtVKFN2N{OgdIhwe3Cqb4L5cIF1cW:wNYfVb2lnOjF|NUO1OVE>
U937Mk\3RY51cWKjY4TldolidCCDc4PhfS=>MojHOVAh|ryPNF;te5I1QCCqM{fZeWROW09?NEP1dnZKdmS3Y3XzJIFvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCC5aXzkJJR6eGViTHXnbY9v\WyuYTDwcoV2dW:yaHnsZUBRcGmuYXTlcJBpcWFvMTDKVlMzKGmwIGW5N|ch[2WubIO=Mn7WNlEyPDJzME[=
U937MkLkRY51cWKjY4TldolidCCDc4PhfS=>Mnq5OVAh|ryPNVzDfJdUPDhiaB?=M2rObmROW09?MUDEc4V{KG6xdDDpcoR2[2ViYX70bYJi[3SncnnhcEBi[3Srdnn0fUBi\2GrboP0JG1KWCCycn;0[YlvNWSnZnnjbYVvfCCOZXfpc45mdGyjIIDu[ZVud3CqaXzhJGpTOzJvMjDpckBWQTN5IHPlcIx{NGL0TY8zOTF2MkGwOi=>
U937NUi0SJRSSW62aXLhZ5RmemmjbDDBd5NigQ>?MXu1NEDPxE1?MVi0PEBpNWT4ZWlsTE2VTx?=M{\CSWRw\XNibn;0JIlv\HWlZTDhcpRq[mGldHXybYFtKGGldHn2bZR6KGGpYXnud5QhTXOlaHXybYNpcWFiY3;sbUBJSjFyMTDpckBWQTN5IHPlcIx{NV\GZnVDOjFzNEKxNFY>
MCF-7NYi2d4E4SXW2b4DoZYd6KEG|c3H5MknzN|Ahdk1?MVq0JIg>NV;OOHlRTE2VTx?=NUnzeYtSUW6mdXPld{BifXSxcHjh[5k>MWSyNFAzQDF|NB?=
U87MGM1vPS2tqdmG|ZTDBd5NigQ>?M2DWSVEh|ryPNFfhU4Q3KGh?NV7NRnFSTE2VTx?=MX\Qc5RmdnSueTDpcohq[mm2czDtWG9TNW2nZHnheIVlKFN4IIDoc5NxcG:{eXzheIlwdg>?NWXXTlBjOTl6NEi0NFQ>
U87MGM1y2W2tqdmG|ZTDBd5NigQ>?NIXpVocyKM7:TR?=NHf5epM3KGh?NGi4[lVFVVORM4\FdnBwfGWwdHz5JIlvcGmkaYTzJFRGSlBzKGS3NEkheGixc4Doc5J6dGG2aX;uNV\vT|g4OTl6NEi0NFQ>
U87MGMn\aT4lv[XOnIFHzd4F6MXKxJO69VQ>?M1X1ZVYhcA>?MofUSG1UVw>?M4THSGRw\XNibn;0JIlvcGmkaYSgcXRQWi2vZXTpZZRm\CCDa4SgdIhwe3Cqb4L5cIF1cW:wNHjvfIYyQTh2OESwOC=>
U87MGNWn4OIMyU2mwYYPlJGF{e2G7NFPROFMyKM7:TR?=MljsOkBpMWHEUXNQMXTEc4V{KG6xdDDpcohq[mm2IGCtOGVDWDFqVEO3M|Q3MSCyaH;zdIhwenmuYYTpc44>NWj1e4ZMOTl6NEi0NFQ>
COS7 cells expressing EGFP-HDQ74/rhebM1\pd2F2fG:yaHHnfUBCe3OjeR?=MnLPNE4zKM7:TR?=MUmyOEBpNVfzd4NETE2VTx?=NXTtRlRUUW6mdXPld{BifXSxcHjh[5k>MmHhNVg{QTF7NEm=
COS7 cells expressing EGFP-LC3M2DHXGF2fG:yaHHnfUBCe3OjeR?=NG\EXHAxNjJizszNMVeyOEBpMYPEUXNQMXLJcoR2[2W|IHH1eI9xcGGpeR?=NED5NWQyQDN7MUm0PS=>
H4NV:ydpdoTnWwY4Tpc44hSXO|YYm=MUewMlIh|ryPM3LHflI1KGh?NEi4XZBFVVORNWDsWnpxUW6lcnXhd4V{KHSqZTDyZZRqdyCxZjDsbYdpfCClaHHpckA{KHO3YoXubZQhOiC2bzDsbYdpfCClaHHpckA{KHO3YoXubZQhOSCrbjDoeY1idiCKNDDj[Yxtew>?NGLzNY0yQDB{NEW4OC=>
HeLaNHz4VGhHfW6ldHnvckBCe3OjeR?=MmHjNVAxKG6PMYqzOkBpNH\VXYhFVVORNXjDS4hJUW6mdXPld{BHWkJiS{KwPVVRNCCWMkC5PGwtKFd{MUCxSkBufXSjboSteYJqeXWrdHnuR{BqdnSncnHjeIlwdg>?M1vH[|E4PTZ|M{i1
HeLaNF;qT2NHfW6ldHnvckBCe3OjeR?=NHqzc5QyODBibl2=MXKzOkBpMmLPSG1UVw>?MUHJcoR2[2W|IF\SRkBYOjFyMV[gcZV1[W62LYXibZF2cXSrblOgbY51\XKjY4Tpc44>M3zFbFE4PTZ|M{i1
HeLaMnfKSpVv[3Srb36gRZN{[Xl?NF\pfYwyODBibl2=MYCzOkBpMVTEUXNQNYHoOIVVUW6mdXPld{BHWkJvRlvCVEBkd22ybHX4JIlvfGW{YXP0bY9vNIDGNXoyPzV4M{O4OS=>
SYFM{\ZXWZ2dmO2aX;uJGF{e2G7Ml\iNVAxKG6PNXfYdGRMOjRiaB?=NUPi[W9RTE2VTx?=M3nCWmlv\HWlZYOgSnJDNU[NQmCgZ49ueGyneDDpcpRmemGldHnvci=>M4i4dFE4PTZ|M{i1
SYFM2HsbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWqxNFAhdk1?M1WzRlI1KGh?NW\pV2JRTE2VTx?=M3fXemlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDTXWYh[2WubIO=NFLYWIwyPzV4M{O4OS=>
HEK293TNEPkenFCdnSrdnnyZYwhSXO|YYm=NFXvdoUyKG6PNFz2N3M1KGR?MVjEUXNQNXLVR2cxUW6mdXPld{BidnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIGK1JJdqfGhiRVO1NEBw\iByLkGgcm0>NH7iVlgyPzR6NUWwNS=>
HEK293TNHnJXJVCdnSrdnnyZYwhSXO|YYm=M3TadFEhdk1?MmLGOEBlM{nkN2ROW09?MnO1TY5lfWOnczDhcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDITXYyKFh2IIfpeIghTUN3MDDv[kAxNjNibl2=NF7iVIEyPzR6NUWwNS=>
PBMCNInkN5pHfW6ldHnvckBCe3OjeR?=NUT2ZZdYOSCwTR?=M3eyclE1KGR?MYDEUXNQNEfUbWNT\WS3Y3XzJGNEWjViZHXud4l1gQ>?MnniNVc1QDV3MEG=
PBMCNWD4U|JTTnWwY4Tpc44hSXO|YYm=NVzVRlhQOSCwTR?=MnHTNVQh\A>?MmnuSG1UVw>?MnnuSI9meyCwb4SgZYZn\WO2IFPYR3I1KGSnboPpeJk>MlrRNVc1QDV3MEG=
HEK293 cellsNEP1epRMcW6jc3WgRZN{[Xl?MUG1NEBvVQ>?MUe0OUBucW5?M3j4d2ROW09?MVPJcohq[mm2czDtWG9TKGurbnHz[UBi[3Srdnn0fUB4cXSqIFnDOVAhd2ZiMD6xJI5OMWSxO|M2ODl3Mx?=
Drosophila melanogaster S2 cells transfected with N-luc and C-lucNX;NWmRYTnWwY4Tpc44hSXO|YYm=NVv6NoNXOTByIH7NNWrSfFE4PCCqNYrEdFdWTE2VTx?=NYjSUnZsUW6mdXPld{BtfWOrZnXyZZNmKHC{b4TlbY4hfHKjboOtd5BtcWOrbnegbY4hTHKxc3;wbIlt[SCvZXzhco9o[XO2ZYKgV|Ih[2WubIOgeJJidnOoZXP0[YQhf2m2aDDOMYx2[yCjbnSgR{1tfWN?NYThN3VYOTdzMkiyOlI>
Human mixed lymphocyteM17WZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnPUOUBvVQ>?M2fQeWROW09?NXLFTYZiUUN3ME2xMlYhdk1wNYD5NJhXOTZzOEW4OlU>
Lewis rat lymph node cellsNYLSZld3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVHaTYRtPSEQvF2=MWDEUXNQMn\FTWM2OD1{Lk[g{txOM17BWlE3OTh3OE[1
cells from the thymus of normal BALB/c miceMWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4e2[|ExKG6PMmTSO|IhcA>?MUTEUXNQM1\ldGlvcGmkaYTzJIx6dXCqb4Dyc4xq\mW{YYTpc44hMEyDRjmge4l1cCCLQ{WwJI9nKDNibl2=MnPqNVAxOjF7NEi=
MRK-nu-1M{\mTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX33V4pOUUN3ME2wMlg1PSCyTR?=MUfTRW5ITVJ?
OCUB-MMYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH7XWZhKSzVyPUWuNlQheE1?NVLrfpBGW0GQR1XS
SF539M2jNWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmDLTWM2OD1zMT62JJBOMkDvV2FPT0WU
ES4MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEf5N5BKSzVyPUKxMlUheE1?MYjTRW5ITVJ?
RL95-2M{nOUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3\LeGlEPTB;MUC3JJBONXL6XpUzW0GQR1XS
LC-2-adNHrte|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4\w[GlEPTB;NEKzJJBONYi5OG1VW0GQR1XS
DaudiMVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUjIblZNUUN3ME20N|QheE1?MW\TRW5ITVJ?
NTERA-S-cl-D1MmDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3rkbmlEPTB;NESzJJBOM3TNW3NCVkeHUh?=
OS-RC-2MknxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWPzR5VYUUN3ME22OVIheE1?MoDIV2FPT0WU
VA-ES-BJNWTkRY5DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoC4TWM2OD15MkOgdG0>M4HUTHNCVkeHUh?=
GR-STM{Pqd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGTv[2VKSzVyPUi0OkBxVQ>?NVW4SFBZW0GQR1XS
SW872NGjJemNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUPD[2FZUUN3ME24OFYheE1?NIDERYFUSU6JRWK=
NOS-1Ml3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUDJR|UxRTh5MTDwUS=>MWDTRW5ITVJ?
MC116MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYjJR|UxRTl6NTDwUS=>NYXzUoo3W0GQR1XS
NCI-H1355M3PLVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV;YUmNtUUN3ME2xMlAyKG6PNFnVRVRUSU6JRWK=
RPMI-8226MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFXXdnJKSzVyPUGuNVkhdk1?NWK1S2pGW0GQR1XS
TE-15MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnHrTWM2OD1zLkO2JI5ONXfncoFYW0GQR1XS
Ramos-2G6-4C10NWDINHQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXrwVmhNUUN3ME2xMlQ3KG6PMUTTRW5ITVJ?
KU812M1:5bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3PWcWlEPTB;Mj6wNUBvVQ>?NUW2eZJrW0GQR1XS
EW-1MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHLWRnlKSzVyPUKuNVchdk1?NGHDUnNUSU6JRWK=
KS-1MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml[0TWM2OD1{LkS1JI5OMX7TRW5ITVJ?
SK-LMS-1M1Lhfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoXOTWM2OD1{LkS5JI5OMX;TRW5ITVJ?
TGBC1TKBM2jKO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX\WbVFyUUN3ME2yMlY6KG6PM{jSdnNCVkeHUh?=
TE-6M2jDXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIi3UYRKSzVyPUKuO|chdk1?NWD4O21vW0GQR1XS
ETK-1M1\SZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MULJR|UxRTJwOEKgcm0>M4LkW3NCVkeHUh?=
BE-13MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1GxdWlEPTB;Mj65PUBvVQ>?NIL6cIJUSU6JRWK=
A3-KAWMlXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1X3U2lEPTB;Mj65PUBvVQ>?NH\yflZUSU6JRWK=
TE-10MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{X5d2lEPTB;Mz6zJI5ONITZTmtUSU6JRWK=
DOHH-2M2nRU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnzETWM2OD1|LkO1JI5OMV;TRW5ITVJ?
ES6MkS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoHxTWM2OD1|LkSzJI5OM3WwbXNCVkeHUh?=
OPM-2MnfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVr2RnVvUUN3ME20MlE2KG6PM{LGWHNCVkeHUh?=
SH-4NEnVeZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUXJR|UxRTRwM{Sgcm0>NV7ySlZKW0GQR1XS
NB13MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFjY[W5KSzVyPUSuN|Yhdk1?NFvJS|lUSU6JRWK=
HUTU-80M{H1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF61cIxKSzVyPUSuOFIhdk1?NUT4XJBwW0GQR1XS
CCRF-CEMMWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUfHUm1[UUN3ME20Mlk1KG6PNGXtbpVUSU6JRWK=
TGBC24TKBMYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX7JR|UxRTVwNUGgcm0>NGj1S2NUSU6JRWK=
697MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUHJR|UxRTZwMkigcm0>MWPTRW5ITVJ?
J-RT3-T3-5MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWHJR|UxRTZwNE[gcm0>MYfTRW5ITVJ?
KALS-1M1HseGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWLJR|UxRTZwNU[gcm0>NVf4bpJlW0GQR1XS
no-10NVTq[3d3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVnJR|UxRTdwMkmgcm0>MW\TRW5ITVJ?
SK-NEP-1MlriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NITHfWhKSzVyPUiuO|khdk1?NIPhTo1USU6JRWK=
L-540NHLadZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoTTTWM2OD1zMD60NkBvVQ>?M2XLcXNCVkeHUh?=
JiyoyeP-2003MlLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUXJR|UxRTFyLkm0JI5OMUPTRW5ITVJ?
HHNX6xendPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEThN21KSzVyPUGxMlM6KG6PM4W0e3NCVkeHUh?=
SRNFXuW|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2PpN2lEPTB;MUGuOFUhdk1?M{\s[HNCVkeHUh?=
QIMR-WILM1v2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF3TUlFKSzVyPUGxMlg2KG6PNHnaRohUSU6JRWK=
A4-FukMVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXrFfWRoUUN3ME2xN{4yOiCwTR?=M2\PXnNCVkeHUh?=
CESSMmj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2HoeWlEPTB;MUOuNVMhdk1?M17GPXNCVkeHUh?=
KE-37M3vDZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHnOc5pKSzVyPUG2MlA4KG6PNHLh[mhUSU6JRWK=
SK-UT-1MmDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGjsdYJKSzVyPUG2MlgyKG6PM2PyTXNCVkeHUh?=
SIG-M5MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4LSdWlEPTB;MUeuNlUhdk1?NWK3e3FzW0GQR1XS
HTNYPIdJFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYTJR|UxRTF5Lk[gcm0>NYXqWm5SW0GQR1XS
DELNVf0VYJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUfG[ZI1UUN3ME2xO{46QSCwTR?=NEXJTZFUSU6JRWK=
SK-PN-DWNHf3TY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3HjZmlEPTB;MkCuNlMhdk1?Ml7jV2FPT0WU
RPMI-8402NFfEc2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGfzeoVKSzVyPUKxMlc4KG6PMlnYV2FPT0WU
RPMI-6666NEjNb|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFPGO2NKSzVyPUK0MlQzKG6PMnTiV2FPT0WU
NCI-H720NV23OodNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml3YTWM2OD1{NT60NUBvVQ>?MVHTRW5ITVJ?
EW-16NGnzN2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIrL[JhKSzVyPUK2Mlg4KG6PNHuwdFVUSU6JRWK=
BL-70NHXpeZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkP4TWM2OD1{OD6zPEBvVQ>?MX7TRW5ITVJ?
SF126MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFzueIVKSzVyPUOwMlM5KG6PMXfTRW5ITVJ?
BC-1NYThSmRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEXGdmhKSzVyPUOxMlI3KG6PM3fnO3NCVkeHUh?=
MHH-PREB-1NXzKcHFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4XPXmlEPTB;M{KuOFQhdk1?NFjIUnNUSU6JRWK=
A101DMWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXXjOmFSUUN3ME2zNk43OiCwTR?=NFSzeXdUSU6JRWK=
NMC-G1M{K2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV[0SZFEUUN3ME2zN{43PyCwTR?=NEnHTlVUSU6JRWK=
LB1047-RCCNVzCdmxiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnHMTWM2OD1|ND62PUBvVQ>?M{e3WHNCVkeHUh?=
EM-2Mn\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYHJR|UxRTN6LkWzJI5OMnrtV2FPT0WU
COLO-684NVPjTGJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXXJR|UxRTN7Lkigcm0>NGrNOlRUSU6JRWK=
BeckerMnnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX7JR|UxRTRzLkC1JI5OMUfTRW5ITVJ?
BL-41MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NITST|BKSzVyPUSzMlY3KG6PNV\4fYRIW0GQR1XS
MDA-MB-134-VINH25SmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mk\sTWM2OD12ND6wNkBvVQ>?NIe0RWJUSU6JRWK=
L-363M1LKXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX\JR|UxRTR2LkezJI5OM3W3VnNCVkeHUh?=
ECC4NH3Te3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV34T3hkUUN3ME20OE44QCCwTR?=NUKyWG9JW0GQR1XS
A388M2jZe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF65dlNKSzVyPUS0MlgzKG6PM4\lRXNCVkeHUh?=
HELMYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGPBeHJKSzVyPUS5Mlc6KG6PMmjrV2FPT0WU
RKONX3hVWh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWezXpl3UUN3ME21NE4zQSCwTR?=M1LMcHNCVkeHUh?=
KINGS-1NX7RRpV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkWxTWM2OD13MT61OUBvVQ>?M{T4NnNCVkeHUh?=
EB-3MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2HFfWlEPTB;NUKuOlchdk1?M1XOd3NCVkeHUh?=
ARH-77MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnS4TWM2OD13Mj64JI5ONVvlelhyW0GQR1XS
GCIYNGTLTW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXfqcopTUUN3ME21N{41PiCwTR?=Mn7BV2FPT0WU
NCI-H1304NHHMV3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmD6TWM2OD13Nz6yNkBvVQ>?NEXDPIdUSU6JRWK=
KARPAS-299MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{LqWmlEPTB;NkGuPFIhdk1?MV7TRW5ITVJ?
IA-LMM1LMd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3rEWGlEPTB;NkiuNVMhdk1?NGW4eYtUSU6JRWK=
GI-1M2GyTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{Xi[2lEPTB;N{CuN|khdk1?MlHtV2FPT0WU
TE-11MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXvJR|UxRTd5LkG3JI5OMnqwV2FPT0WU
LS-411NNWT1Tpk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYj2Wmx1UUN3ME23O{42PyCwTR?=NInhfFlUSU6JRWK=
no-11Mnv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIq3W5JKSzVyPUizMlI1KG6PMkHIV2FPT0WU
MV-4-11NXrsfGdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVfLOoJMUUN3ME24N{44OyCwTR?=NVrSR3l{W0GQR1XS
BV-173NXfTS5BPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX\JR|UxRTh|Lkm3JI5OMlnWV2FPT0WU
CMKMlzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX63XmoyUUN3ME24OE4yPiCwTR?=NIn0T|dUSU6JRWK=
LC4-1NYTsTVF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoXVTWM2OD16Nj63NkBvVQ>?NFLCNGRUSU6JRWK=
COR-L279NEnhWlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV;vOI9FUUN3ME24O{4zPSCwTR?=MXHTRW5ITVJ?
NCI-H209NWnBXZpsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGHl[nhKSzVyPUi3MlQyKG6PNXe1XG93W0GQR1XS
RajiNYjwXYxyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHjtd3NKSzVyPUi5MlczKG6PMnjIV2FPT0WU
LB996-RCCM4DzWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnzpTWM2OD17Mz60N{BvVQ>?NEPvblFUSU6JRWK=
NCI-H526MlTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2rGfWlEPTB;OUOuOVkhdk1?M{PhUnNCVkeHUh?=
KGNMorSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NETib3FKSzVyPUm2MlI6KG6PMX3TRW5ITVJ?
MOLT-4MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGDEUZhKSzVyPUm2Mlc6KG6PMmfCV2FPT0WU
PF-382M2[2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWnJR|UxRTl4Lke5JI5ONWG2R2ZiW0GQR1XS
BC-3M4\wdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTl7LkG4JI5OM4fuPHNCVkeHUh?=
KARPAS-422NX\aNXhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH64OVVKSzVyPUGwNk4xQSCwTR?=MV\TRW5ITVJ?
SBC-1MkX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2LnbWlEPTB;MUC3Mlc2KG6PM1jZVXNCVkeHUh?=
LC-1FNV:1XZNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3\OUGlEPTB;MUC4MlA2KG6PNFS2WIZUSU6JRWK=
GB-1NXfkdWJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH\aUGFKSzVyPUGwPU4xOiCwTR?=MX;TRW5ITVJ?
SNB75MlPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnjrTWM2OD1zMUmuOlkhdk1?NH\3UW9USU6JRWK=
BB65-RCCNW[2U5h4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoHITWM2OD1zMUmuPVMhdk1?Ml62V2FPT0WU
NCI-N87M1fz[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGLaZWNKSzVyPUGyNU46QCCwTR?=NFHE[GhUSU6JRWK=
IST-MEL1NX\hV3loT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUPJR|UxRTF{Mj6zPEBvVQ>?NHfaU5dUSU6JRWK=
HOP-62NFnIWFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NETj[YVKSzVyPUGyOk45QSCwTR?=NYTGT5ZzW0GQR1XS
ACNNWrkUYtOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MY\JR|UxRTF2Nj63OUBvVQ>?MX3TRW5ITVJ?
DMS-114NXHSdIV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn\uTWM2OD1zNUCuOlchdk1?M2q4SHNCVkeHUh?=
MLMAMkXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{\n[mlEPTB;MUW5Mlg5KG6PMYDTRW5ITVJ?
HT-144MlPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXOyPIlzUUN3ME2xOlUvPDNibl2=Mm\MV2FPT0WU
C2BBe1MnzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NI\PPZVKSzVyPUG2O{44PiCwTR?=MVrTRW5ITVJ?
L-428MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3zKVGlEPTB;MUe3Mlchdk1?MoT5V2FPT0WU
DU-4475NWXyfGJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoPGTWM2OD1zOEeuOlghdk1?Mnu1V2FPT0WU
CP67-MELMVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2TBdGlEPTB;MUm5MlM5KG6PM{fVeHNCVkeHUh?=
MEG-01M2XBbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGnCW41KSzVyPUKwNU46PiCwTR?=M4SxSHNCVkeHUh?=
IST-SL2M1XmWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4HRPWlEPTB;MkC4MlY{KG6PNYnIRYVWW0GQR1XS
ES8NEnOU4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHrIfphKSzVyPUKyOU46PCCwTR?=MluyV2FPT0WU
COLO-800NVXYbnlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFHlcW9KSzVyPUKzOU4zQCCwTR?=M4ry[3NCVkeHUh?=
MFH-inoM{Pke2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2r0TWlEPTB;MkO1Mlg1KG6PMWHTRW5ITVJ?
OVCAR-4MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mo\0TWM2OD1{M{euNlQhdk1?M1\QUHNCVkeHUh?=
PSN1NXW0UWY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVPJR|UxRTJ2Mj63NUBvVQ>?MlixV2FPT0WU
EW-12MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVXhV5F1UUN3ME2yOFMvOSCwTR?=MVfTRW5ITVJ?
HCC1599M{LpVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYPD[ZhWUUN3ME2yOlEvPDdibl2=MYDTRW5ITVJ?
SJSA-1NHTKVGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml\YTWM2OD1{N{GuOFYhdk1?NG\SNGNUSU6JRWK=
ST486NF3T[mdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHnRcmdKSzVyPUK5Ok4yPCCwTR?=NWG1fGZXW0GQR1XS
NOMO-1MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkPMTWM2OD1|MECuNlEhdk1?MVjTRW5ITVJ?
MN-60M3zrcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NI\ZfYNKSzVyPUOwOU4{OiCwTR?=Mn;JV2FPT0WU
HCC1187MkToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlPzTWM2OD1|MEeuNlUhdk1?NHHjdWlUSU6JRWK=
SW982MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWLJR|UxRTNzND63OUBvVQ>?MUDTRW5ITVJ?
LB647-SCLCMlHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV\DcI9uUUN3ME2zNlgvPzFibl2=Mn\iV2FPT0WU
HC-1M1\FT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUXJR|UxRTN|NT61JI5OMVzTRW5ITVJ?
EHEBM3\aOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV;JR|UxRTN|Nz61NkBvVQ>?NUO1OWlpW0GQR1XS
TURMXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3j5R2lEPTB;M{[zMlk2KG6PNHLZ[VRUSU6JRWK=
LU-139NHjDc5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{XxZWlEPTB;M{e4MlAzKG6PNYruTmYzW0GQR1XS
NB1MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkTTTWM2OD1|OESuOFUhdk1?NXjWdlVXW0GQR1XS
BB30-HNCNHHIeoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmHjTWM2OD1|OEiuN|Ihdk1?MX;TRW5ITVJ?
HAL-01NG\GOmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NY\LdJJHUUN3ME2zPFkvOjZibl2=NUPseIdOW0GQR1XS
K5NV75V|k1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{DHPGlEPTB;NEGxMlM4KG6PMlfEV2FPT0WU
MZ2-MELMnjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVzJR|UxRTRzMz62OEBvVQ>?MXrTRW5ITVJ?
RXF393MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF;icWJKSzVyPUSxOk41PSCwTR?=MVfTRW5ITVJ?
NCI-H1648MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVi4RVg3UUN3ME20NVcvPTNibl2=MXrTRW5ITVJ?
TE-12MmP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4rwbGlEPTB;NEO0MlI3KG6PMX\TRW5ITVJ?
EoL-1-MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUnJR|UxRTR|Nz65PEBvVQ>?NWHSZ5c{W0GQR1XS
JARMkO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MU\JR|UxRTR|OD62NkBvVQ>?M3;1eXNCVkeHUh?=
DSH1MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX7JR|UxRTR3OD65NUBvVQ>?NGPjeoJUSU6JRWK=
NCI-H187NGH4NWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoTOTWM2OD12NkKuPFEhdk1?MYXTRW5ITVJ?
HCE-4M4LGeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1XW[mlEPTB;NEe3MlY3KG6PMYfTRW5ITVJ?
8-MG-BANFTXfoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWKweGEzUUN3ME21PFEvPTJibl2=NYLQeXhDW0GQR1XS
KLENHjwXHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml\HTWM2OD13OEWuNkBvVQ>?MnLMV2FPT0WU
KNS-42NVTEWVV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1mwUmlEPTB;NUi2MlgyKG6PM{D4NnNCVkeHUh?=
MSTO-211HMn;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEDONHRKSzVyPU[wPU44PCCwTR?=NHywfIhUSU6JRWK=
GDM-1M2W3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYDJR|UxRTZzND6wPUBvVQ>?NXflem5oW0GQR1XS
TE-1NUG4PHVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnrBTWM2OD14NE[uNVIhdk1?NFPDXFVUSU6JRWK=
BT-474MmDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmrSTWM2OD14NEeuNFYhdk1?NXfKTJNNW0GQR1XS
KARPAS-45NGPoWYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUHpfHlXUUN3ME22OFcvPiCwTR?=NHfaWGNUSU6JRWK=
MOLT-16M{jyOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYDQSWxkUUN3ME22OFcvQTNibl2=MVHTRW5ITVJ?
KURAMOCHINVrGcmxPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX\nSZpZUUN3ME22OVcvPTFibl2=NInON2JUSU6JRWK=
K-562NV3PcppLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4fRbmlEPTB;Nk[5MlUyKG6PNHX0XW1USU6JRWK=
EKVXNEm0cmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH;5[INKSzVyPU[3Nk44OSCwTR?=NHnuZohUSU6JRWK=
GAKMkfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MULJR|UxRTZ5NT6zJI5ONHPHe4RUSU6JRWK=
NCI-SNU-5M2Ppdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH\BUZdKSzVyPU[5NE4xOSCwTR?=MYrTRW5ITVJ?
NCI-H2126M3vJXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmS2TWM2OD15Mk[uPFchdk1?MoPjV2FPT0WU
CTV-1Mo[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXyzcnFsUUN3ME23OFQvQSCwTR?=NFrqVWRUSU6JRWK=
SW962MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4PJbmlEPTB;N{S4MlQ1KG6PNV;RNGlJW0GQR1XS
MONO-MAC-6NVXZNFZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoTvTWM2OD15NU[uPVMhdk1?MVjTRW5ITVJ?
NCI-H748NXvZbIpUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX3JR|UxRTd3OD65PUBvVQ>?NHTKVZdUSU6JRWK=
NCI-H524MonxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYPJR|UxRTd6MD63N{BvVQ>?NH[wV5FUSU6JRWK=
LS-123NHLjd3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4LvS2lEPTB;N{m1MlY6KG6PMmT6V2FPT0WU
NB7M3nDSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVHJR|UxRThzND6xOEBvVQ>?NUPsW5h[W0GQR1XS
LS-1034M3fWNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4KxWWlEPTB;OEK4Mlk5KG6PM4\WeXNCVkeHUh?=
TE-5MnHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX34V5ZiUUN3ME24PFMvPTZibl2=NGfQVXJUSU6JRWK=
A704NVG4fYJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV7JR|UxRTh7OT6xOUBvVQ>?M4PEOHNCVkeHUh?=
TK10NHznOHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoP1TWM2OD17MU[uNFMhdk1?NWTxTphqW0GQR1XS
NCI-H345NUPzN2xQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnTmTWM2OD17NEOuNlIhdk1?MVjTRW5ITVJ?
CGTH-W-1Ml;QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUXJR|UxRTl2OD6xN{BvVQ>?M17FfXNCVkeHUh?=
NCI-H510ANUTWUXZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX\JR|UxRTl6NT6xNkBvVQ>?Ml2zV2FPT0WU
NCI-H1963M4jRNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXyyN2RIUUN3ME2xMlA{Ojl{IN88US=>NV3oVo9FW0GQR1XS
SCC-3NHm3WYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3nhcmlEPTB;MT6wN|QyPCEQvF2=MlqxV2FPT0WU
EW-11NVTGRXNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXmzdJNNUUN3ME2xMlA5PzR|IN88US=>MkjxV2FPT0WU
CPC-NMlnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3XhNGlEPTB;MT6wPFgh|ryPM1PTUnNCVkeHUh?=
NCI-H1417NEjWOJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4HSSGlEPTB;MT6xNlI3KM7:TR?=M3jvRXNCVkeHUh?=
DG-75MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NImyXXRKSzVyPUGuNVYzQDVizszNM2TRNXNCVkeHUh?=
HD-MY-ZMon3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWfJR|UxRTFwMU[0NVYh|ryPNYPjWJE2W0GQR1XS
ATN-1MlzmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH:1O5ZKSzVyPUGuNlYzODlizszNMXXTRW5ITVJ?
KM-H2NHf2XXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1zHU2lEPTB;MT6yOlQxQCEQvF2=Mn;hV2FPT0WU
NCI-H2081NVTWfZdGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4LjPWlEPTB;MT6yOlY{PyEQvF2=MV;TRW5ITVJ?
HL-60M3\Eemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHrneJJKSzVyPUGuNlY6PTlizszNMYLTRW5ITVJ?
DBM4X3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWnBe4x3UUN3ME2xMlI4OjR{IN88US=>MUHTRW5ITVJ?
NCI-H1522MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX7DTFI2UUN3ME2xMlI5QDh5IN88US=>M3vXUnNCVkeHUh?=
AM-38NHv0cmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVjkOpNTUUN3ME2xMlMxPzJizszNNGnrTY1USU6JRWK=
NCI-H446NH:wVGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXm1XG5KUUN3ME2xMlMzOTJzIN88US=>NWjCWGZ[W0GQR1XS
SU-DHL-1MoTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3u1TmlEPTB;MT6zNlgxOSEQvF2=NHPFXppUSU6JRWK=
NH-12MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{HJOGlEPTB;MT6zOlM4PCEQvF2=MkHkV2FPT0WU
DMS-79M1PSPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWHueoVTUUN3ME2xMlM3QDZ4IN88US=>MVjTRW5ITVJ?
NCI-H716MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUDJR|UxRTFwM{i5PFYh|ryPNXHuUZIyW0GQR1XS
ML-2M1rYZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVfmZ3BFUUN3ME2xMlQyPTJ7IN88US=>MkTpV2FPT0WU
NB10NW\qVppvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlPzTWM2OD1zLkS2OlMzKM7:TR?=MYfTRW5ITVJ?
ONS-76NFiwb|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYDJR|UxRTFwNUO1Olkh|ryPMlXQV2FPT0WU
LOUCYNXTFfW06T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX3JR|UxRTFwNUS2OVch|ryPMXfTRW5ITVJ?
SCLC-21HMnjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmfWTWM2OD1zLkW4OVgzKM7:TR?=M1q5fHNCVkeHUh?=
TGWM4m5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYDEVocxUUN3ME2xMlY{QTd3IN88US=>MnHEV2FPT0WU
LXF-289MnOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3zrOWlEPTB;MT63N|I3QCEQvF2=M4XzPXNCVkeHUh?=
BB49-HNCNHPjU4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYnJR|UxRTFwN{O1PFYh|ryPMYHTRW5ITVJ?
NCI-H747M2jnXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGGxWmNKSzVyPUGuO|U{PDZizszNNX3EPGRUW0GQR1XS
LU-165NGjsZWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXPlcVNZUUN3ME2xMlg1QTh4IN88US=>MmLUV2FPT0WU
OMC-1MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2fpS2lEPTB;MT65OVA3PiEQvF2=M{\BbXNCVkeHUh?=
RCC10RGBNGPHTVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mly2TWM2OD1zLkm1PFE4KM7:TR?=M{K4ZXNCVkeHUh?=
SW684NHXYO3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmCzTWM2OD1zLkm2NFk6KM7:TR?=MmHhV2FPT0WU
TE-8NVrqZmZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlfxTWM2OD1{LkC1OVU6KM7:TR?=MknlV2FPT0WU
SK-N-DZMoHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEDafWVKSzVyPUKuNVMzPzRizszNM4\KcnNCVkeHUh?=
EVSA-TM2mySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlPMTWM2OD1{LkG3N|E2KM7:TR?=MmjFV2FPT0WU
KASUMI-1MnHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV3JR|UxRTJwMUi4NVUh|ryPNX24[XZjW0GQR1XS
NKM-1M1\Ed2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mk\oTWM2OD1{LkK1OFczKM7:TR?=MUfTRW5ITVJ?
CAL-148MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV3JR|UxRTJwM{O2NVQh|ryPMl\YV2FPT0WU
NCI-H64NHXoNo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWjJR|UxRTJwM{SyN|Ih|ryPNVi4[JNpW0GQR1XS
KNS-81-FDMoHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGDUUGpKSzVyPUKuN|Y3OiEQvF2=NI\3RY1USU6JRWK=
KM12NWHtTXlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXLtc4ZCUUN3ME2yMlQxQDN7IN88US=>NUH4NG03W0GQR1XS
SW954NX2wcJcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIL5bW5KSzVyPUKuOFc4PzlizszNNFvveIdUSU6JRWK=
NCI-H1395MnzVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4PYWmlEPTB;Mj61NlY1PSEQvF2=MUTTRW5ITVJ?
DJM-1M3PBdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4GwXWlEPTB;Mj62NFY{KM7:TR?=NHKxN2FUSU6JRWK=
COLO-668Mnm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHHsR5JKSzVyPUKuPFI3QTVizszNM1u5TXNCVkeHUh?=
NCI-H1436M1nOcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnTFTWM2OD1{Lki1OlE2KM7:TR?=M37RcXNCVkeHUh?=
LB2241-RCCNV7yeXZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFvvTXlKSzVyPUKuPFY5OzlizszNMne1V2FPT0WU
GT3TKBM{\OTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkW0TWM2OD1{Lki5NFU2KM7:TR?=MY\TRW5ITVJ?
COLO-824M4rG[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXzROZI1UUN3ME2yMlg6PzZ6IN88US=>NYXvNm1lW0GQR1XS
ES1MknzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{fmUmlEPTB;Mj64PVg4QSEQvF2=MWTTRW5ITVJ?
LB771-HNCNH;PSXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2job2lEPTB;Mj65NFk1PiEQvF2=MXvTRW5ITVJ?
GI-ME-NMXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIL1doZKSzVyPUOuNFA6ODRizszNMYHTRW5ITVJ?
NALM-6M2j0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml3qTWM2OD1|LkCwPVM{KM7:TR?=NFfUN2FUSU6JRWK=
LU-134-ANXXucolnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVHJR|UxRTNwMEW0NlUh|ryPM{PpfXNCVkeHUh?=
DMS-153M2Hj[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml3STWM2OD1|LkC1PFI1KM7:TR?=M3PlXXNCVkeHUh?=
MZ1-PCM1XYdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2raOmlEPTB;Mz6wPVA4QCEQvF2=NWXrXJROW0GQR1XS
NCI-H1155M{i2W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX6wbYxxUUN3ME2zMlEyPjFizszNMUfTRW5ITVJ?
CAS-1MoDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXrnepJXUUN3ME2zMlE{PzB5IN88US=>NHLGb2VUSU6JRWK=
D-502MGM4TyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYfKe5N5UUN3ME2zMlE1OzlizszNM1m0d3NCVkeHUh?=
NCI-H2141MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWTJR|UxRTNwMUe0OVIh|ryPNX\WWWdlW0GQR1XS
NB6MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGDmVlZKSzVyPUOuNVgzPTlizszNMoLMV2FPT0WU
NCCITM4fkUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEDhRlRKSzVyPUOuNlE5ODlizszNMUXTRW5ITVJ?
NB69MnviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2XIdWlEPTB;Mz6zNVg6OSEQvF2=MYfTRW5ITVJ?
JVM-2NVfOeYtqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH3VXIpKSzVyPUOuN|Y1OzNizszNMWPTRW5ITVJ?
K052NFnseIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkDKTWM2OD1|LkO3PVY5KM7:TR?=M3eyOHNCVkeHUh?=
HCC2157NGL1fnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2PO[mlEPTB;Mz61N|IzQCEQvF2=NELvdYRUSU6JRWK=
KMOE-2Mn3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MofjTWM2OD1|LkW0NlQzKM7:TR?=NGrFW5BUSU6JRWK=
SF268NYLneIRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4K1TWlEPTB;Mz63NVU2PCEQvF2=NGL4RW1USU6JRWK=
CHP-126MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX3JR|UxRTNwN{[0OVgh|ryPMX\TRW5ITVJ?
CP66-MELNGDxOHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUPkNZJPUUN3ME2zMlc6ODl2IN88US=>MXLTRW5ITVJ?
NCI-H69NHLMOHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFrhWpVKSzVyPUSuNFE6OzZizszNM3LzUnNCVkeHUh?=
A253M4D3[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYfJR|UxRTRwMEKxNFEh|ryPMVTTRW5ITVJ?
NB14MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUGzNmRLUUN3ME20MlExPDd7IN88US=>M133XHNCVkeHUh?=
NCI-H1694MlOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEfF[3dKSzVyPUSuNVMyOTJizszNMmrCV2FPT0WU
NCI-H2196NF\1cmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH7LfGJKSzVyPUSuNVcyPjlizszNMlPDV2FPT0WU
TE-9MnT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnfJTWM2OD12LkG3OVgzKM7:TR?=NFfLfnNUSU6JRWK=
D-283MEDMkDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4LNbWlEPTB;ND6xPFg1KM7:TR?=M4P1OXNCVkeHUh?=
OCI-AML2MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVvOO3Y6UUN3ME20MlE6PDh7IN88US=>MlvaV2FPT0WU
D-263MGNET4UVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3\QVmlEPTB;ND6yNlk3OSEQvF2=NGPvcoZUSU6JRWK=
MPP-89M4\USGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{C0PWlEPTB;ND6yO|MxPCEQvF2=NIDjSVVUSU6JRWK=
LAMA-84NXy5SVNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXfOV|dCUUN3ME20MlMxPDJzIN88US=>NHvWSYpUSU6JRWK=
LB373-MEL-DMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXGzepR[UUN3ME20MlM3Pzh7IN88US=>NF\B[WRUSU6JRWK=
UACC-257NVOyWG0yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVTJR|UxRTRwM{m1N|Qh|ryPNHi2TWJUSU6JRWK=
MC-CARMm\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUXz[mdGUUN3ME20MlQ{QTlizszNM1XXRXNCVkeHUh?=
COLO-320-HSRNXjpOJhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV\yVGFHUUN3ME20MlQ1PDJ5IN88US=>MYHTRW5ITVJ?
P30-OHKNXTrRWFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHHOXVBKSzVyPUSuOlY2QDFizszNNHH0UGFUSU6JRWK=
UACC-812NUfoOml7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUf5RllxUUN3ME20MlY6OTZzIN88US=>NHXkV4hUSU6JRWK=
CTB-1MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoK1TWM2OD12LkexOVU2KM7:TR?=MkTEV2FPT0WU
ALL-POMkDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFKwUmNKSzVyPUSuPFQxPzdizszNMYjTRW5ITVJ?
SK-MEL-2MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3rKSmlEPTB;ND64Olk2PSEQvF2=M{f0d3NCVkeHUh?=
TC-YIKM4H5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoHSTWM2OD12Lkm3PVQzKM7:TR?=M{XyO3NCVkeHUh?=
NCI-H1882NHLhc|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHHseXFKSzVyPUWuNFIxODFizszNNGfxPHNUSU6JRWK=
MHH-CALL-2NETlfWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXXJR|UxRTVwMEWwOFIh|ryPNELZZ|dUSU6JRWK=
U-87-MGMnjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmDWTWM2OD13LkC5OFY3KM7:TR?=NIGzNo9USU6JRWK=
NCI-H1092MoOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{K0c2lEPTB;NT6yOlU2PSEQvF2=M3\JVXNCVkeHUh?=
TE-441-TMlPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX\JR|UxRTVwMke4NkDPxE1?M371R3NCVkeHUh?=
SK-MEL-1MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXvJR|UxRTVwMkmwOFQh|ryPMmfKV2FPT0WU
EW-22MoPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX3QV5A4UUN3ME21MlI6PDZ4IN88US=>M3fSeHNCVkeHUh?=
MZ7-melMYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{\0cGlEPTB;NT60NFY6OSEQvF2=NXX6VXZwW0GQR1XS
LP-1MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NULrZYxCUUN3ME21MlQyOjlzIN88US=>NFj1OXBUSU6JRWK=
NCI-SNU-16NUj2SGc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHPtRXdKSzVyPUWuOlQxPzRizszNMYHTRW5ITVJ?
LU-65MkPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3e5TmlEPTB;NT63OlM4OyEQvF2=NGi5bYdUSU6JRWK=
CW-2M4T3Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXHJR|UxRTVwOEW5OVkh|ryPNH3COGZUSU6JRWK=
WSU-NHLMoDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFPjfWJKSzVyPUWuPVUyPzRizszNMoLMV2FPT0WU
IST-MES1MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoPsTWM2OD13Lkm1OFQ{KM7:TR?=M3HwNXNCVkeHUh?=
U-266MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH64U2JKSzVyPUWuPVgzODJizszNMlPuV2FPT0WU
TALL-1MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2Xwe2lEPTB;Nj6xOFY5QCEQvF2=NWfGWmxlW0GQR1XS
Calu-6M3roemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWG3ZVBrUUN3ME22MlE2OzF4IN88US=>MULTRW5ITVJ?
MMAC-SFMofHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NELQfZVKSzVyPU[uNVg2PTZizszNMn70V2FPT0WU
NCI-H82NXXYdW1qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUTJR|UxRTZwMkC0PFkh|ryPNF\PdlBUSU6JRWK=
RS4-11Mnj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXnJR|UxRTZwMkW4PVch|ryPNUPITms6W0GQR1XS
SNU-C2BNH22XG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnH0TWM2OD14LkSwPVY6KM7:TR?=NVTZVY9uW0GQR1XS
BOKUMkPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXHJR|UxRTZwNEe1PVch|ryPNUHHdlhuW0GQR1XS
C8166NXzPXWdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoP1TWM2OD14LkW1PVEzKM7:TR?=NYXsTnU3W0GQR1XS
D-247MGNHHIU4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mlf0TWM2OD15LkC0N|Q4KM7:TR?=NWfJeZpoW0GQR1XS
EW-18NXzwdplvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mmm4TWM2OD15LkC3NlkzKM7:TR?=NXv2TW9CW0GQR1XS
KG-1NXLWXnp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NE\ZZ3RKSzVyPUeuOlI4OzhizszNNFPaPWFUSU6JRWK=
REHMofNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4fCUGlEPTB;Nz62PFExQSEQvF2=NGi1SpNUSU6JRWK=
U-698-MMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX:4UJJCUUN3ME23Mlg1OzF3IN88US=>MlnFV2FPT0WU
KP-N-RT-BM-1NYLCfGRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWLJR|UxRTdwOUOwNlkh|ryPMYLTRW5ITVJ?
MS-1MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NY\yOIVxUUN3ME23Mlk3ODRzIN88US=>NI\GT29USU6JRWK=
SNU-C1M2\PVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHy3[4pKSzVyPUeuPVgyQTJizszNNI\UVY5USU6JRWK=
SK-MM-2NE\vVFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NULZUG1VUUN3ME24MlI3ODZ3IN88US=>Mn7MV2FPT0WU
LAN-6M4jENGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mny4TWM2OD16LkOwNFAyKM7:TR?=NXvkTpE5W0GQR1XS
NEC8MlTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUnFV3BpUUN3ME24MlMxPjlzIN88US=>NXLHVoxHW0GQR1XS
NCI-H1770MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2\PRWlEPTB;OD6zPFAxOiEQvF2=MYnTRW5ITVJ?
D-336MGNH71SJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2DuNmlEPTB;OD60NFEyPiEQvF2=M3O0e3NCVkeHUh?=
COLO-829MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX3JR|UxRThwNEi4O|kh|ryPMXTTRW5ITVJ?
LS-513MkiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVLJR|UxRThwNUm1PVkh|ryPNF3GWFlUSU6JRWK=
YTMnrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{X5PGlEPTB;OD62NlQzPyEQvF2=MVPTRW5ITVJ?
EW-24M4TUe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NG\Fc25KSzVyPUiuO|Y2PCEQvF2=NXf4WINnW0GQR1XS
IST-SL1MoTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2q2[WlEPTB;OD64OlU1OyEQvF2=NI\iem9USU6JRWK=
CA46MoTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MU\JR|UxRThwOUWwPVgh|ryPNYjHb3NlW0GQR1XS
NCI-H1838NUf2VIRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{TadmlEPTB;OD65PFYxOiEQvF2=NGXucZVUSU6JRWK=
NCI-H719NV;L[GZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mlq4TWM2OD17LkK1Nlc6KM7:TR?=NIXM[FlUSU6JRWK=
HCE-TNEjCXVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFi4SplKSzVyPUmuN|A5PTFizszNMmK2V2FPT0WU
A498MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn;XTWM2OD17LkO2NVI1KM7:TR?=NYL3b2M2W0GQR1XS
LB831-BLCMXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mk\oTWM2OD17Lke2OVIyKM7:TR?=NYTrTGZEW0GQR1XS
SKM-1MlHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MW\JR|UxRTlwOEW5OlMh|ryPMXzTRW5ITVJ?
THP-1MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXLVOXJxUUN3ME25Mlk3QTF6IN88US=>NYXybJFUW0GQR1XS
SHP-77Mn7jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF30SXVKSzVyPUGwMlQxPyEQvF2=NYX4[INTW0GQR1XS
EW-3NHLJXnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnPFTWM2OD1zMD62Nlg6KM7:TR?=MmfyV2FPT0WU
KY821NGDOdGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHL6XmtKSzVyPUGwMlc3OyEQvF2=MV;TRW5ITVJ?
NCI-SNU-1M{eydmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NE\teG5KSzVyPUGxMlAzOTdizszNM1\hTHNCVkeHUh?=
HCC2218NYGySGg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHXtOVVKSzVyPUGxMlM6QDZizszNMkPJV2FPT0WU
IM-9M17zOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4fOVmlEPTB;MUGuOVExPiEQvF2=NHe1WFZUSU6JRWK=
NCI-H889NYmxWYpsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1\pW2lEPTB;MUGuOVMyOyEQvF2=M2\xc3NCVkeHUh?=
HDLM-2MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnrKTWM2OD1zMj60NVU6KM7:TR?=MYnTRW5ITVJ?
LB2518-MELMVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlTFTWM2OD1zMj62PFE2KM7:TR?=M1jQPHNCVkeHUh?=
NCI-H23M{PkVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFPHPIpKSzVyPUGzMlI1OjVizszNNXTyXGNOW0GQR1XS
NB17NFzLSHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHr0fJJKSzVyPUGzMlQ2PzlizszNNWLST2FJW0GQR1XS
NCI-H322MNFfRdYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmruTWM2OD1zND60NFY5KM7:TR?=NVjTb3FwW0GQR1XS
SUP-T1MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml3oTWM2OD1zND60NVMh|ryPMn;yV2FPT0WU
ES3MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUXkU2doUUN3ME2xOU4xPzB|IN88US=>NEHRRnZUSU6JRWK=
ES5NEjpNJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{DNSGlEPTB;MUWuNFc5PyEQvF2=MVfTRW5ITVJ?
NCI-H1650NF\wSG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlXjTWM2OD1zNT60PVc6KM7:TR?=MoD5V2FPT0WU
NCI-H226M{LL[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NE\hRZZKSzVyPUG1Mlg4PjhizszNNVzm[I84W0GQR1XS
COR-L88MoXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1\NXWlEPTB;MU[uN|E1KM7:TR?=Mn3tV2FPT0WU
SCC-15NHPTTm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHntOYNKSzVyPUG2MlM5PjlizszNNYLEZmdkW0GQR1XS
GOTONIf0RZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWXIZldzUUN3ME2xOk41Pzl|IN88US=>NV3EUlBRW0GQR1XS
SIMAM4fQSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3nSTWlEPTB;MU[uOFgxOiEQvF2=M{jiOXNCVkeHUh?=
NCI-H1299MoLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2S3VmlEPTB;MUeuNVU6OSEQvF2=MmLvV2FPT0WU
NCI-H1581MnzTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MonaTWM2OD1zNz60NlE6KM7:TR?=MWTTRW5ITVJ?
MHH-NB-11NHX3dIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH3uWI5KSzVyPUG3Mlk3QDNizszNNHPOdGNUSU6JRWK=
MFM-223MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWDJR|UxRTF6LkC1N|gh|ryPNWrZdogzW0GQR1XS
ES7NFLmT5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NW\rT3o4UUN3ME2xPE42PDNzIN88US=>MUjTRW5ITVJ?
JVM-3MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnrFTWM2OD1zOD63NVch|ryPNIrTeXhUSU6JRWK=
RLMor2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHPzZnRKSzVyPUKwMlM5QCEQvF2=NH\HVHFUSU6JRWK=
EC-GI-10NGrLfHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2Lkd2lEPTB;MkGuNlA1OSEQvF2=M37jS3NCVkeHUh?=
LNCaP-Clone-FGCM2fVWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIT2bZRKSzVyPUKxMlY4PjhizszNNFTp[5JUSU6JRWK=
IMR-5MmHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYLJR|UxRTJzLki0PVQh|ryPM2PnNXNCVkeHUh?=
KP-N-YSNXOyUYZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX7JR|UxRTJzLki3OUDPxE1?M1vYPHNCVkeHUh?=
Mo-TM{jTeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH\RSFJKSzVyPUKyMlIyQDVizszNMlfjV2FPT0WU
NCI-H128M{XkVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M13JbWlEPTB;MkOuOVg2OyEQvF2=NYrjXGNkW0GQR1XS
RH-1NH\PRmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4[xWWlEPTB;MkOuO|g3PiEQvF2=M1uxWHNCVkeHUh?=
NCI-H2171NX;oeXYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mnm4TWM2OD1{ND6yOFg2KM7:TR?=MUPTRW5ITVJ?
RPMI-8866NWjNR2pDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{\zTWlEPTB;Mk[uO|QzKM7:TR?=M3\ybnNCVkeHUh?=
SK-N-FIMoqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NY\NVIJ1UUN3ME2yO{4{QDFzIN88US=>MofJV2FPT0WU
LOXIMVIM4LjOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFezXI1KSzVyPUK3MlgxPTFizszNNVfB[GNmW0GQR1XS
P31-FUJNHLXeVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVXH[2RlUUN3ME2zNU42Ozd2IN88US=>MV3TRW5ITVJ?
KMS-12-PEM1;ZcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYPzOolbUUN3ME20PU42OzB{IN88US=>M3vPbXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]
Features

Protocol(Only for Reference)

Kinase Assay:

[1]

Immunoblotting for the mTOR kinase assay HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr

Cell Assay:

[3]

Cell lines U87-MG, T98G, and U373-MG
Concentrations Dissolved in DMSO, final concentrations ~25 μM
Incubation Time 72 hours
Method

Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.

Animal Study:

[7]

Animal Models Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
Formulation Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
Dosages ~4 mg/kg/day
Administration Injection i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Edwards SR, et al. J Biol Chem, 2007, 282(18), 13395-13401.

[2] Barbet NC, et al. Mol Biol Cell, 1996, 7(1), 25-42.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-06-18)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02240407 Not yet recruiting Pompe Disease University of Florida October 2016 Phase 1
NCT02793544 Not yet recruiting Myelodysplastic Syndrome (MDS)|Chronic Lymphocytic Leukemia (CLL)|Chemotherapy-sensitive Lymphoma|Acute Lymphoblastic Leukemia (ALL)/T Lymphoblasti  ...more Myelodysplastic Syndrome (MDS)|Chronic Lymphocytic Leukemia (CLL)|Chemotherapy-sensitive Lymphoma|Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma|Acute Myelogenous Leukemia (AML)|Acute Biphenotypic Leukemia (ABL)|Acute Undifferentiated Leukemia (AUL) Center for International Blood and Marrow Transplant Rese  ...more Center for International Blood and Marrow Transplant Research|National Marrow Donor Program|Resource for Clinical Investigation in Blood and Marrow Transplantation August 2016 Phase 2
NCT02642094 Not yet recruiting Cancer of Breast The University of Texas Health Science Center at San Antonio July 2016 Phase 0
NCT02768116 Not yet recruiting Coronary Heart Disease Beijing Anzhen Hospital June 2016 --
NCT02753309 Not yet recruiting Bladder Cancer The University of Texas Health Science Center at San Antonio May 2016 Phase 0

view more

Chemical Information

Download Rapamycin (Sirolimus) SDF
Molecular Weight (MW) 914.18
Formula

C51H79NO13

CAS No. 53123-88-9
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms AY 22989,NSC-2260804
Solubility (25°C) * In vitro DMSO 20 mg/mL (21.87 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 0.5% CMC+0.25% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone

Customer Product Validation(12)


Click to enlarge
Rating
Source Nat Genet 2014 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck
Method Western blot
Cell Lines Persister cells
Concentrations 10 nM
Incubation Time 3 days
Results While added with a specific mTOR inhibitor, rapamycin(Rapa), it inhibitied endogenous mTOR activity, showed that markedly reduced MYC protein levels in persister cells but not in naive T-ALL cells.

Click to enlarge
Rating
Source Cancer Cell 2011 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck
Method Cell viability Analysis
Cell Lines Ar+murine (CaP8) and human (LNCaP) prostate cancer cells, Pb-Cre+;PtenL/L mice, Pb-Cre+;PtenL/L;ArL/Y mice
Concentrations 1 nM, 4 mg/kg
Incubation Time 0-4 weeks
Results These data suggest that CaPs with AR loss have greater reliance upon the PI3K/AKT/mTOR-signaling pathways and that combined AR/androgen blockage in conjunction with PI3K/AKT/mTOR inhibition (by Rapamycin) is more effective for CaPs initiated by PTEN loss or PI3K/AKT activation.

Click to enlarge
Rating
Source Cell Res 2012 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck
Method EdU labeling
Cell Lines MCF-7 cells
Concentrations 150 nM
Incubation Time 48 h
Results The punctate structures from SRC-3 or MIF knockdown cells are very similar to that found in cells treated with rapamycin, a known inducer of autophagy.

Click to enlarge
Rating
Source Autophagy 2015 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck
Method Cell imaging
Cell Lines H4-LC3-GFP cells
Concentrations 200 nM
Incubation Time 24 h
Results Consistent with inhibition of autophagy, the levels of LC3-II were lower and the levels of SQSTM1/p62 were higher in this USP18 knockdown cell line compared to that of control under basal conditions as well as the induced condition after the treatment with rapamycin.

Click to enlarge
Rating
Source Cell Rep 2015 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck
Method Western blotting
Cell Lines HEK293 cells
Concentrations 250 nM
Incubation Time 24 h
Results Rapamycin virtually abolishes stimulation by Rheb of phospho-S6 kinase and phospho-4EBP1 but has negligible effects on phospho-eIF2a (A). In contrast to phosphorylation of eIF2a, which is not mediated by mTORC1, phosphorylation of other elongation factors does involve mTORC1. Thus, rapamycin prevents phosphorylation of eIF4G and eIF4B, targets of S6K, but not eIF2a (B). By contrast, rapamycin, as expected, abolishes phospho-S6 kinase but fails to influence phospho-eIF2a, phospho-Erk or phospho-Akt (C).

Click to enlarge
Rating
Source Biochem Pharmacol 2015 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck
Method Immunofluorescence
Cell Lines RAW264.7 cells
Concentrations 10 uM
Incubation Time 16 h
Results It has been reported that autophagy can directly regulate inflammatory responses. To confirm this phenomenon, we pre-treated RAW264.7 cells with 3-MA (an autophagy inhibitor by blocking the class III PI3Ks) or rapamycin (an autophagy inducer by targeting the negative regulators against autophagy as mammalian target of rapamycin (mTOR)), followed by addition of LPS. LPS-induced punctate LC3 was markedly reduced and enhanced in the presence of 3-MA and rapamycin, respectively.

Click to enlarge
Rating
Source Biochem Pharmacol 2011 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck
Method Western blot
Cell Lines H1299 cells
Concentrations 2 μM
Incubation Time 48 h
Results RAD001 and other mTOR inhibitors decreased the levels of survivin protein, as assessed by Western blot analysis, without affecting the levels of other IAP members. In addition, combined treatment with sorafenib and mTOR inhibitor Rapamycin and RAD001 decreased survivin expression to a greater extent than treatment with either alone.

Click to enlarge
Rating
Source J Lipid Res 2011 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck
Method Histological analysis, immunohistochemistry, Liver triglyceride content analysis, real-time PCR
Cell Lines Male SD rats
Concentrations
Incubation Time 7 d
Results To determine the effect of rapamycin, an mTOR inhibitor, in the OA-induced fatty liver, rats were fed 1% OA and administered rapamycin for seven days. OA-induced lipid accumulation was completely inhibited by the treatment with rapamycin (Fig. A). HE and Oil Red O staining of liver sections clearly confi rmed the results (Fig. B). Immunohistochemistry analyses showed signifi cantly repressed SREBP-1 in the rapamycin-cotreatment liver ( Fig. B ). All the downstream effectors of SREBP-1, such as Lxr-α, Acc, Scd-1 and Fas, were consistently suppressed by rapamycin ( Fig. C ).

Click to enlarge
Rating
Source Biochim Biophys Acta 2013 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck
Method Measurement of cytosolic free Ca2+concentration ([Ca2+]c )
Cell Lines Human platelets
Concentrations 500 nM
Incubation Time 30 min
Results Rapamycin administration significantly reduced TG-evoked Ca2+ -entry by 19. 5 ?9.4 %.

Click to enlarge
Rating
Source Tuberc Respir Dis 2013 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck
Method Microscope imaging
Cell Lines NCI-H1299 cells
Concentrations 10 uM
Incubation Time 48 h
Results Growth inhibition induced by rapamycin or erlotinib is enhanced by combination treatment with monensin in NCI-H1299 cells.

Click to enlarge
Rating
Source 2013 Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck
Method Western Blot
Cell Lines HeLa cells
Concentrations 0/2/20/200 nM
Incubation Time 24 h
Results

Click to enlarge
Rating
Source 2011 Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck
Method Western blot
Cell Lines
Concentrations
Incubation Time 0-6 h
Results Rapamycin inhibits growth-dependent TCTP induction.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related mTOR Products

  • MHY1485

    MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.

  • CHIR-99021 (CT99021)

    CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively.

  • Dorsomorphin

    Dorsomorphin is a potent, reversible, selective AMPK inhibitor with Ki of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.

  • Everolimus (RAD001)

    Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay.

  • AZD8055

    AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. Phase 1.

    Features:First drug to inhibit both types of mTOR protein.

  • Torin 1

    Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.

  • Temsirolimus (CCI-779, NSC 683864)

    Temsirolimus (CCI-779, NSC 683864) is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay.

  • INK 128 (MLN0128)

    INK 128 (MLN0128) is a potent and selective mTOR inhibitor with IC50 of 1 nM in cell-free assays; >200-fold less potent to class I PI3K isoforms, superior in blocking mTORC1/2 and sensitive to pro-invasion genes (vs Rapamycin). Phase 1.

  • Tacrolimus (FK506)

    Tacrolimus (FK506) is a 23-membered macrolide lactone, it reduces peptidyl-prolyl isomerase activity in T cells by binding to the immunophilin FKBP12 (FK506 binding protein) creating a new complex.

  • KU-0063794

    KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2 with IC50 of ~10 nM in cell-free assays; no effect on PI3Ks.

Recently Viewed Items

Tags: buy Rapamycin (Sirolimus) | Rapamycin (Sirolimus) ic50 | Rapamycin (Sirolimus) price | Rapamycin (Sirolimus) cost | Rapamycin (Sirolimus) solubility dmso | Rapamycin (Sirolimus) purchase | Rapamycin (Sirolimus) manufacturer | Rapamycin (Sirolimus) research buy | Rapamycin (Sirolimus) order | Rapamycin (Sirolimus) mouse | Rapamycin (Sirolimus) chemical structure | Rapamycin (Sirolimus) mw | Rapamycin (Sirolimus) molecular weight | Rapamycin (Sirolimus) datasheet | Rapamycin (Sirolimus) supplier | Rapamycin (Sirolimus) in vitro | Rapamycin (Sirolimus) cell line | Rapamycin (Sirolimus) concentration | Rapamycin (Sirolimus) nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us